Patents by Inventor Kathryn J. Hofmann

Kathryn J. Hofmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding human papilloma virus type 18
    Patent number: 6908615
    Abstract: The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: June 21, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George
  • DNA encoding human papillomavirus type 6A
    Patent number: 6290965
    Abstract: The present invention is directed to DNA molecules encoding purified human papillomavirus type 6a and compounds derived therefrom.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Kathrin U. Jansen, Kathryn J. Hofmann
  • Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein
    Patent number: 6159729
    Abstract: The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 12, 2000
    Assignee: Merck & Co., Ltd.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George, E. Dale Lehman
  • Recombinant papillomavirus vaccines
    Patent number: 5888516
    Abstract: Recombinant expression vectors encoding the L1 and L2 proteins of papillomavirus, methods of making and using the recombinant proteins and purified virus-like particles comprised of the recombinant proteins are provided.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: March 30, 1999
    Assignee: Merck & Co. Inc.
    Inventors: Kathrin U. Jansen, James C. Cook, III, Hugh A. George, Kathryn J. Hofmann, Joseph G. Joyce, Ernest Dale Lehman, Henry Z. Markus, Mark Rosolowsky, Loren S. Schultz
  • DNA encoding human papillomavirus type 18
    Patent number: 5840306
    Abstract: The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: November 24, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper
  • Expression of human interleukin-1.beta. in a transgenic animal
    Patent number: 5824837
    Abstract: A transgenic mouse has been prepared that expresses a human interluekin-1.beta. transgene. Expression of the transgene is mediated by a mouse metallothionein promoter. As a result of the expression of this transgene, the mouse has inflammation of its kidney and liver. The claimed animals are useful as screening tools for agents that are potentially useful for treating inflammation.
    Type: Grant
    Filed: April 22, 1996
    Date of Patent: October 20, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Howard Y. Chen, Kathryn J. Hofmann, Leonardus H. T. Van Der Ploeg, Alan R. Shaw, Myrna E. Trumbauer, Hui Zheng
  • Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
    Patent number: 5821087
    Abstract: The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Robert Lowe, Joseph G. Joyce, Hugh A. George, Kathryn J. Hofmann, Kathrin U. Jansen, E. Dale Lehman, Michael P. Neeper
  • Trains of yeast for the expression of heterologous genes
    Patent number: 5068185
    Abstract: The GAL4 protein is rate-limiting in quantity as a positive regulator for galactose-inducible promoters in strains of yeast. Novel strains are described in which the GAL4 protein can be overproduced in a regulatable fashion. These strains are useful for the regulatable expression in yeast of heterologous genes whose expression is driven by a galactose-inducible promoter.
    Type: Grant
    Filed: July 10, 1986
    Date of Patent: November 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: James E. Hopper, Loren D. Schultz, Kathryn J. Hofmann, Ronald W. Ellis